Se­ri­ous side ef­fects side­line small Roche study of an ex­per­i­men­tal Hunt­ing­ton’s drug from Io­n­is

Two years af­ter in-li­cens­ing an ex­per­i­men­tal an­ti­sense drug for Hunt­ing­ton’s dis­ease from Io­n­is, Roche in­ves­ti­ga­tors have been forced to halt a small ear­ly-stage study in the wake of a pair of se­ri­ous side ef­fects.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER